Using Reward-based Biomarkers To Improve The Early Detection Of Bipolar Disorder In Individuals Seeking Treatment For Depression
Funder
National Health and Medical Research Council
Funding Amount
$366,252.00
Summary
Bipolar disorder is often misdiagnosed as unipolar major depression, which can have disastrous clinical consequences. Emerging evidence indicates that individuals with bipolar disorder show particular dysfunctions within brain regions involved in processing reward. This research will use cutting-edge neuroscience methodologies to investigate reward processing in these two disorders, with the objective of identifying biological markers that help distinguish bipolar from unipolar depression.
Brain Connectivity Imaging Markers To Confirm Diagnosis For Bipolar Vs. Unipolar Depression – A Connectome Approach.
Funder
National Health and Medical Research Council
Funding Amount
$434,369.00
Summary
Differentiating Bipolar disorders from Unipolar Depression is a major clinical challenge. This misdiagnosis hinders optimal clinical care and has many deleterious consequences such self-harm, increased chances of suicide, poor prognosis, and greater health care costs related to this disorder. This project will provide urgently-needed advance in accurate identification of Bipolar disorders using Magnetic Resonance Imaging and remove one of the key obstacles to accurate diagnosis.
Understanding And Predicting Freezing Of Gait In Parkinson's Disease.
Funder
National Health and Medical Research Council
Funding Amount
$380,580.00
Summary
Freezing of Gait (FOG) affects half of all patients with Parkinson’s Disease (PD) with episodes causing the feet to feel glued to the ground leading to a significant falls risk. The mechanisms underlying FOG are not well understood and current treatments are usually ineffective. Combining brain wave recording, eye-tracking and functional brain scanning we will identify the changes that precipitate an episode of FOG allowing the development of a non-invasive device to prevent falls.
The Prevention, Early Detection, & Effective Management Of Neurocognitive Disorders In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$4,929,014.00
Summary
The unprecedented greying of the world population is posing a major challenge to health care in meeting the needs of older individuals with cognitive disorders such as Alzheimer�s disease. At the same time, drugs are being developed to prevent these disorders, or to treat them effectively. Our proposal is a comprehensive attempt at dealing with the neuropsychiatric aspects of these neurocognitive disorders. Our group is endeavouring to better define the early stages of these disorders, and study ....The unprecedented greying of the world population is posing a major challenge to health care in meeting the needs of older individuals with cognitive disorders such as Alzheimer�s disease. At the same time, drugs are being developed to prevent these disorders, or to treat them effectively. Our proposal is a comprehensive attempt at dealing with the neuropsychiatric aspects of these neurocognitive disorders. Our group is endeavouring to better define the early stages of these disorders, and studying methods of detecting them at an early stage, using the latest neuropsychological and neuroimaging techniques. We wish to investigate new drugs for the prevention of dementia. Much of dementia is not treated early because of lack of training of primary care physicians in identifying dementia, and we are developing methods to deal with this problem. We are also examining the role of cognitive disorders in accidents and suicides in the elderly, and the development of depression. We are determining the role of psychiatric disorders in the care of these patients, and the methods of alleviating the burden of disease. We expect that this research will make a major impact on health policy for these disorders in Australia. We also hope to make our Program the premier centre for training in geriatric neuropsychiatry.Read moreRead less
Prevention, Early Detection And Effective Management Of Neurocognitive Disorders In The Elderly
Funder
National Health and Medical Research Council
Funding Amount
$6,547,975.00
Summary
The Program comprises a number of longitudinal studies of ageing individuals to develop methods of diagnosing dementia before symptoms become prominent. We are also examining factors that increase the risk of developing dementia. We wish to translate this research into early and better diagnosis, and the development of new treatments and strategies for dementia care. We expect that this research will make a major impact on health policy in Australia for cognitive disorders in the elderly.
Predictors Of Response To Antidepressants: Utility Of Behavioural, Neuroimaging And Genetics Data
Funder
National Health and Medical Research Council
Funding Amount
$310,071.00
Summary
Major depressive disorder (MDD) is projected to cause the second greatest global burden of disease by 2020, highlighting the urgent need for valid predictors of effective treatment response. Currently, there are no accurate predictors of response to antidepressants in MDD, and successful treatment relies greatly on 'trial and error'. This process is demanding on health resources, and may be a factor in the high suicide rates in depressed patients. Previous research on treatment response has been ....Major depressive disorder (MDD) is projected to cause the second greatest global burden of disease by 2020, highlighting the urgent need for valid predictors of effective treatment response. Currently, there are no accurate predictors of response to antidepressants in MDD, and successful treatment relies greatly on 'trial and error'. This process is demanding on health resources, and may be a factor in the high suicide rates in depressed patients. Previous research on treatment response has been limited by recruitment of small, heterogeneous patient samples, lack of placebo control, and a failure to examine task related activity in brain imaging studies. Perhaps one of the more troubling aspects of research that aims to predict treatment response to antidepressant medications is the use of commonly used outcome measures such as the Hamilton Rating Depression Scale (HAM-D), which were developed long before current classification systems of depression came into use. The US Federal Drug Administration has recently identified what they call a translational gap such that behavioural and biological measures are the most robust for detection of disorders such as depression, yet these measures remain to be translated into clinical tools that can be used to evaluate treatment. The aim of the current study therefore is to determine whether genetic variability is related to treatment outcome as defined by a more objective outcome measure (facial expression perception) using a randomised controlled design. The study will also determine whether brain measures (fMRI, EEG) enhance the prediction of SSRI response to both clinical and behavioural measures, over and above the genetic contribution.Read moreRead less
Identifying Neuroimaging Based Biomarkers For Predicting Clinical Progression Along The Lewy Body Disease Spectrum
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Lewy body dementias (LBD) comprise similar but heterogenous group of poorly understood disabling neurodegenerative conditions. This project aims to apply advanced neuroimaging techniques and novel psychological testing to patients at risk of Lewy body disorders as well individuals with established disease to identify novel biomarkers that may explain symptoms of these disorders as well as help predict development of LBD at its early stages when it may be amenable to neuroprotective treatments.